Abstract:Objective To assess the therapeutic effects of flupentixol and melitracen tablets combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome (IBS) accompanied with anxiety and depression.Methods This multi-center,randomized,prospective study enrolled 84 patients with diarrhea-predominant IBS who were divided into combined treatment group (42 patients) and control group (42 patients).Saccharomyces boulardii was administrated in both of the groups,and flupentixol and melitracen was added in combined treatment group.The treatment course was four weeks.The gastrointestinal symptoms and mood disorders were evaluated before treatment,one week and four weeks after treatment.Adverse reactions were also observed.Chi-square test was performed for statistical analysis.Results At the end of one week after treatment,the efficacy rates of gastrointestinal symptoms improvement of combined treatment group and control group were 31.0％ (13/42) and 23.8％ (10/42),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rate of gastrointestinal symptoms improvement of combined treatment group was 92.5％ (37/40),which was higher than that of control group (73.2％,30/41),and the difference was statistically significant (x2 =5.291,P =0.037).At the end of one week after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group and control group were 31.6％ (12/38) and 12.1％ (4/33),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group was 63.9％ (23/36),which was higher than that of control group (34.4％,11/42),and the difference was statistically significant (x2 =6.433,P=0.043).At the end of one week and four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group were 35.7％ (15/42) and 80.0％ (32/40),which were higher than those of control group (15.4％,6/39 and 34.2％,13/38),and the differences were statistically significant (x2 =9.759,P=0.007; x2 =17.105,P＜0.01).One week after treatment,the adverse events rates of combined treatment group and control group were 4.8％ (2/42) and 4.8％ (2/42) ; four weeks after treatment,the adverse events rates of combined treatment group and control group were 2.5％ (1/40) and 2.4％ (1/41).There was no statistically significant difference in adverse events rates between two groups (both P＞0.05).Conclusions Flupentixol and melitracen combined with Saccharomyces boulardii treatment could not only improve the anxiety and depression symptoms of patients with diarrhea-predominant IBS,but also effectively improve gastrointestinal symptoms.The efficacy of combined treatment is better than monotherapy Saccharomyces boulardii alone treatment.

Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders.

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Clinical efficacy of omeprazole combined mosapride in treating reflux esophagitis

Quality of Life and Cost-Effectiveness of Combined Therapy for Reflux Esophagitis.

Evaluation of therapeutic effects of flupentixol and melitracen combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome accompanied with anxiety and depression

Effect of Clinician-Patient Communication on Compliance with Flupentixol-Melitracen in Functional Dyspepsia Patients

Behavior Intervention Therapy in Patients with Gastroesophageal Reflux Disease

The Benefits Of Combination Therapy With Esomeprazole And Rebamipide In Symptom Improvement In Reflux Esophagitis: An International Multicenter Study

Benefit of small dose antidepressants for functional dyspepsia: Experience from a tertiary center in eastern China.

A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis

Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease

Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis

Clinicai Investigation on Esomeprazoie Treatment of Sixty-Nine Asthmatic Patients with Gastroesophageal Reflux Symptoms

Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial

A Controlled Study of Wuling Capsule in the Treatment of Patients with Gastroesophageal Reflux Disease Accompanied with Depression

Therapeutic efficacy of flupentixol and melitracen combined with conventional medicine in patients with refractory functional bowel disorders

The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study

<TITLE>COMPARATIVE EFFECTS OF ESOMEPRAZOLE AND OMEPRAZOLE IN TREATING REFLUX ESOPHAGITIS OF THE AGED

Clinical Effect of Esomeprazole Combined with Trimebutine Maleate Tablets for Treatment of Erosive Esophagitis

Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial